Alector, Inc. (ALEC) Stock

Alector, Inc. (ALEC) is a Healthcare stock trading at $1.74 (as of 2026-06-18), with a market capitalization of $197.07M and a trailing P/E of -1.5. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Alector, Inc. is a clinical-stage biopharmaceutical company developing therapies for neurodegenerative diseases, including humanized monoclonal antibody programs such as AL001 in Phase III and AL101 in Phase I, along with additional antibody candidates in earlier clinical phases. Its drug development targets conditions including frontotemporal dementia, Alzheimer’s, Parkinson’s, and amyotrophic lateral sclerosis.

Valuation — source: SEC EDGAR (first-party)
Price	$1.74
Market Cap	$197.07M
P/E Ratio	-1.5
EV / EBITDA	-1.0
Price / Book	18.71
Price / Sales	10.56
DCF Value (model)	$-27.87
DCF Upside vs Price	-1701.7%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$21.05M
Net Margin	-679.2%
Return on Equity	-1207.7%
Debt / Equity	0.94
Current Ratio	5.25
Revenue Growth (YoY)	-79.1%
EPS Growth (YoY)	13.0%
FCF Growth (YoY)	-20.4%

Financial Health — source: SEC EDGAR
Altman Z-Score	-5.08 (distress)

Valuation vs Sector & Industry
Stock P/E	-1.5
Sector P/E (Healthcare)	20.9
Industry P/E (Pharmaceutical Products)	17.0
vs Sector	-107.0%
vs Industry	-108.6%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	TCG Crossover Management, LLC ($21.50M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Arnon Rosenthal
Employees	175
Country	US
IPO Date	2019-02-07

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.